Advancements in NSCLC Treatment

This chapter examines treatment strategies for unresectable stage III non-small cell lung cancer, focusing on key trials that highlight the role of osomertinib in improving patient outcomes. It details the findings of the LORA trial, emphasizing significant improvements in survival rates for patients with EGFR mutations receiving maintenance therapy after chemoradiation.